免疫检查点抑制剂相关性心肌炎的发生机制及表现研究进展  

Mechanism of Immune Checkpoint Inhibitor-associated Myocarditis and Its Clinical Manifestation

作　　者：薛楠 李晓江 XUE Nan;LI Xiao-jiang(National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《中国肿瘤》2021年第7期545-551,共7页China Cancer

基　　金：中国癌症基金会北京希望马拉松专项基金(LC2019A07)。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors,ICI)是一种抗体,包括细胞毒性T淋巴细胞相关蛋白-4(CTLA-4)、程序性细胞死亡蛋白-1(PD-1)和PD-1配体(PD-L1)。ICI可以改善各种晚期癌症的临床预后,但随着临床运用的增加也会出现免疫相关不良反应,例如在心脏不良反应中,心肌炎的发病率虽低,但致死性较高,应该引起临床医生的注意。该文结合ICI的近期研究结果对ICI相关性心肌炎的发生机制及临床表现等方面进行综述。Immune checkpoint inhibitors(ICI), including antibodies to cytotoxic T lymphocyte associated protein-4(CTLA 4), programmed cell death protein 1(PD-1) and PD-1 ligand(PD-L1),have improved the clinical outcomes of some advanced cancers. With the increased clinical use of ICIs, the incidence of cardiac adverse reactions have been reported, among which, special attention should be given to ICI-related myocarditis. The incidence of myocarditis during the ICI therapy is low, but the fatality is high. Based on the latest literatures, in this article, the mechanism and clinical manifestation of ICI-related myocarditis are reviewed.

关 键 词：免疫检查点抑制剂 心肌炎 心脏不良反应 

分 类 号：R256.2[医药卫生—中医内科学]